Scientific Program


Hall A Hall B Hall C

Day 1 : Friday,30thSep 2016

Hall A : Diabetes

9.00-10.30am


10 +5min
10 +5min
10 +5min
22+8min
8 min

Type II diabetes in the young(age<35 yrs.)

  • Chairpersons : J Bax, S Sheikh, S Shah
  • Introduction
  • A young Indian with type 2 diabetes - S Sheikh
  • Challenges & Issues in management - M John
  • C-Peptide measurements in clinical practice - S Shah
  • Imaging for Atherosclerosis - J Bax
  • Q and A
  • Closing Remarks

10.30-12.00noon


15+5min
15+5min
15+5min

22+8min

Beyond blood glucose control

  • Chairpersons : V Lobo, S Kale,S Shah
  • Introduction
  • Self monitoring of BG-A tool to achieve targets - A Shaikh
  • Indian Phenotype : Breaking the nexus with SGLT2i - B Sinha
  • DKD and Non-DKD - V Lobo
  • Diabetes as a cardiovascular disease-the importance of treat-ing diabetic dyslipidaemia - F Raal
  • Q and A
  • Closing Remarks

12.00-1.30pm



16 min
16 min
2 min
2 min
10 min



16 min
16 min
4 min
4 min
5 min

Debates

  • Chairpersons : M Fisher,S Kale, MS Hiremath
  • Introduction
  • Debate 1 - Statins to everyone with diabetes.
  • Proponent - B Saboo
  • Opponent - A Bhoraskar
  • Rebuttal I - B Saboo
  • Rebuttal II - A Bhoraskar
  • Q and A
  • Closing Remarks
  • Debate 2 - Intensive treatment of diabetes reduce CV risk?
  • Proponent - M Fisher
  • Opponent -P Gaede
  • Rebuttal I - M Fisher
  • Rebuttal II - P Gaede
  • Q and A
  • Closing Remarks

1.30-2.30pm

Lunch

2.30-4.00pm


18+4min
18+4min
18+4min
18+4min

Hot topics

  • Chairpersons : A Singh,S Shah,M John
  • Introduction
  • Why SGLT-2 inhibitors actually work - P Gaede
  • Cardio-Renal protection of SGLT-2 inhibition - A Solini
  • Blood Pressure management in diabetes: New insights - S Natarajan
  • The spotlights on Sulphonylureas ! What to choose is the key ! - A Singh
  • Q and A
  • Closing Remarks

4.00-5.30pm


22+8min
22+8min
22+8min

Glycemic Control - Peaks & Valleys

  • Chairpersons : S Kale, A Singh, L Ryden
  • Introduction
  • Patient groups who may not benefit from tight glycemic control - M Fisher
  • Early combination strategies for Type 2 diabetes - S Del Prato
  • Hypoglycemia- A cardiac risk factor-is it a hype? - L Ryden
  • Q and A
  • Closing Remarks

5.30-6.00pm

Break

6.00-7.30pm

10min
22min


22+8min

22+8min

Meet the Legend

  • Chairpersons - MS Hiremath, JJ Dalal, HM Mardikar, R Mathew
  • Introduction - HM Mardikar
  • Pay for disease or invest in health - L Ryden
  • Felicitation ceremony
  • Guest Lectures
  • Individualised approaches to thromboprophylaxis in atrial fibrillation - J Camm
  • Changing landscape of treatment of Aortic Stenosis - J Bax
  • Q and A
  • Closing Remarks - JJ Dalal
Hall A Hall B Hall C

Day 1 : Friday,30thSep 2016

Hall B: Non Invasive Cardiology

9.00-10.30am


18+4min
18+4min
18+4min
18+4min

Newer insights in Hypertension

  • Chairpersons : T MacDonald, T Nair, A Banerjee
  • Introduction
  • Ambulatory BP - U Jadhav
  • Evaluation of renal damage at baseline and during treatment - N Desai
  • Salt and HT - NV Deshpande
  • BP variability - SS Iyenger
  • Q and A
  • Closing Remarks

10.30-12.00noon


18+4min
18+4min
18+4min
18+4min

Challenges in treatment of Hypertension

  • Chairpersons - SS Iyengar, S Natarajan, NV Deshpande
  • Introduction
  • Challenge of treating high BP in young patients - K Venugopal
  • Heart rate control in HT - J J Dalal
  • New Calcium Channel antagonist : Indian perspective - U Jadhav
  • Renal artery angioplasty- for whom? - T MacDonald
  • Q and A
  • Closing Remarks

12.00-1.30pm


18+4min

18+4min
18+4min
18+4min

Controversies in Hypertension Therapy

  • Chairpersons : T Nair, NV Deshpande, N Desai
  • Introduction
  • Clinical practice guidelines - should they be based on only randomised trials? - T MacDonald
  • U.S. guideline for hypertension management: are they correct? - C Granger
  • Systolic blood pressure is still that matters - T Nair
  • Is it the right time for Indian guidelines? - A Banerjee
  • Q and A
  • Closing Remarks

1.30-2.30pm

Lunch

2.30-4.00pm


18+4min
18+4min
18+4min

18+4min

Atrial Fibrillation

  • Chairpersons - SS Iyengar, K Venugopal, U Jadhav
  • Introduction
  • Termination of Acute A Fib - Y Lokhandwala
  • RF ablation : when and how?- S Petkar
  • Risk assessment of stroke and bleeding for patients with atrial fibrillation - C Granger
  • The changing circumstance of atrial fibrillation-progress towards precision medicine
  • Q and A
  • Closing Remarks

4.00-5.30pm


18+4min
18+4min
18+4min
18+4min

Clinical Updates

  • Chairpersons - PP Mohanan, G Koshy, A Bhagwat
  • Introduction
  • Biomarkers for monitoring of HF - S S Iyengar
  • Diuretic therapy at discharge and hyponatremia -N Desai
  • Devices in management of HF - S Petkar
  • Heart rate reduction : what are the options? - JJ Dalal
  • Q and A
  • Closing Remarks

5.30-6.00pm

Break

6.00-7.30pm

10min
22min
8min

22+8min

22+8min

Meet the Legend

  • Chairpersons - MS Hiremath, JJ Dalal, HM Mardikar, R Mathew
  • Introduction - HM Mardikar
  • Pay for disease or invest in health - L Ryden
  • Felicitation ceremony
  • Guest Lectures
  • Individualised approaches to thromboprophylaxis in atrial fibrillation - J Camm
  • Changing landscape of treatment of Aortic Stenosis - J Bax
  • Q and A
  • Closing Remarks - JJ Dalal
Hall A Hall B Hall C

Day 1 : Friday,30thSep 2016

Hall C: Acute Cardiac Care and Invasive Cardiology

9.00-10.30am

5min



15min
15min
2min
2min
5min





15min
15min
2min
2min
10min

Grand Round I

  • Chairpersons - A Dharmadhikari, JJ Dalal, A Jabir
  • Case I - 50 yr old male with a past history of hypertensive bleed presents with acute onset dyspnea - P Shetty
  • Debate the treatment (A Case of PE, thrombolyse or not to thrombolyse)
  • Proponent - A Bhagwat
  • Opponent - P Shetty
  • Rebuttal I - A Bhagwat
  • Rebuttal II - P Shetty
  • Case I - 75yr old male with a history of TIA 4 yrs back has acute AWMI of 1.30hr duration - MS Hiremath
  • Debate the treatment (debate on - thrombolysis VS PCI & staged VS multivessel PCI)
  • Proponent - MS Hiremath
  • Opponent - R Mathew
  • Rebuttal I - MS Hiremath
  • Rebuttal II - R Mathew
  • Q and A

10.30-12.00noon


20+6min
20+6min
20+6min
10min

ACS in Elderly : Case based presentations

  • Chairpersons - Y Loya, G Koshy, Jabir A
  • Introduction
  • Does Age Matter? - B Wrigley
  • Treating ACS in ICU with IV antithrombotic - PP Mohanan
  • Treating elderly patient with Cardiac arrest - S Price
  • Q and A
  • Closing remarks

12.00-1.30pm


5min



15min
15min
2min
2min
5min



15min
15min
2min
2min
10min

90mins with Dual Antiplatelet therapy

  • Chairpersons - HM Mardikar, A Bhagwat, PP Mohanan
  • Introduction
  • Case - 60yr old male has undergone multivessel PCI after ACS - HM
    Mardikar
  • Debate the treatment - Continue Ticagrelor/prasugrel for 1yr
  • Proponent - HM Mardikar
  • Opponent - P Shetty
  • Rebuttal I - HM Mardikar
  • Rebuttal II - P Shetty
  • Case - 70yr old male with diabetes has undergone sensible incomplete revascularization following ACS with multiple stents
  • Debate the treatment (continue DAPT beyond 12 months)
  • Proponent - G Koshy
  • Opponent - B Wrigley
  • Rebuttal I - G Koshy
  • Rebuttal II - B Wrigley
  • Q and A

1.30-2.30pm

Lunch

2.30-4.00pm


8+6min
8+6min
8+6min
8+6min
8+6min
15min

Case Presentations - Rapid Fire

  • Chairpersons - P Shetty, R Mathew, S Sathe
  • Introduction
  • Elderly lady presented with acute LVF - S Price
  • Interesting case of ACS - B Wrigley
  • Case of flash pulmonary edema - A Jabir
  • Young man with A Fib - S Price
  • 66yr old male with diabetes and recurrent syncopal attacks - S Petkar
  • Q and A
  • Closing remarks

4.00-5.30pm


15+5min
15+5min
15+5min
15+5min
5min

Important Insights In Decision Making for Physicians

  • Chairpersons - HM Mardikar, B Wrigley, S Price
  • Introduction
  • PCI VS Thrombolysis In AMI - R Mathew
  • Reperfusion in STEMI - S Sathe
  • Multivessel PCI VS CABG in ACS - A Jabir
  • Left Main - Stenting VS CABG : MS Hiremath
  • Q and A
  • Closing remarks

5.30-6.00pm

Break

6.00-7.30pm

10min
22min


22+8min

22+8min

Meet the Legend

  • Chairpersons - MS Hiremath, JJ Dalal, HM Mardikar, R Mathew
  • Introduction - HM Mardikar
  • Pay for disease or invest in health - L Ryden
  • Felicitation ceremony
  • Guest Lectures
  • Individualised approaches to thromboprophylaxis in atrial fibrillation - J Camm
  • Changing landscape of treatment of Aortic Stenosis - J Bax
  • Q and A
  • Closing Remarks - JJ Dalal

Day 2 : Saturday,1st Oct 2016

Hall A

9.00-10.30am


6min

22+8min
10min
6min

22+8min
10min

Stable angina

  • Chairpersons : J Camm, S Natarajan,P Shetty
  • Introduction
  • Case : Patient of Stable angina was advised medical management after FFR 2yrs back now presents with ACS - MS Hiremath
  • CT imaging : future of evaluation - J Bax
  • back to case discussion
  • Case - 60yr old male has multivessel disease and stable angina for 2yrs - R Mathew
  • State of art medical treatment of stable angina - J Camm
  • back to case discussion
  • Closing remarks

10.30-11.00am

Break

11.00-12.30pm


22+8min

22+8min
22+8min

Cardio-vascular Disease Prevention

  • Chairpersons : PP Mohanan, T Nair, M John
  • Introduction
  • LDL-cholesterol, the pivotal risk factor for atherosclerosis. How low to go and is it safe? - F Raal
  • Optimising HTN Management - N Poulter
  • Adding extra life years with diabetes : Steno 2 experience - P Gaede
  • Q and A
  • Closing remarks

12.30-2.00pm


22+8min

22+8min
22+8min

Drugs for the Heart & Diabetes

  • Chairpersons : HM Mardikar, S Kale
  • Introduction
  • Dual antiplatelet therapy after coronary stents: how long for which patients? - C Granger
  • Incretin-Based Therapies in the Treatment Algorithm - R Defronzo
  • EMPA-REG outcomes one year later - S Del Prato
  • Q and A
  • Closing remarks

2.00-3.00pm

Lunch

3.00-4.30pm


18+4min
18+4min
18+4min

18+4min

Cardio-Diabetes Therapeutics II

  • Chairpersons : K Venugopal,B Saboo,M John
  • Introduction
  • Pathway 3 in treatment of HT - T MacDonald
  • Some aspects on the use of DPP-4 inhibitors - L Ryden
  • Interactive case stydy : Patient is on DPP4 inhibitors now develops HF - M Fisher
  • The natural history of diabetic nephropathy: how things are changing - A Solini
  • Q and A
  • Closing remarks

4.30-6.00pm


22+8min
22+8min
22+8min

Guest lectures

  • Chairpersons : R Mathew, G Koshy, S Shah
  • Introduction
  • What was new at ESC 2016? - J Bax
  • Treating low risk patient of A Fib - J Camm
  • Once-daily delayed-release metformin - R DeFronzo
  • Q and A
  • Closing remarks

6.00-6.30pm

Break

6.30-8.00pm

22+8min
22+8min



16min
4min
16min
4min
10min

Beta Cells.....Beta Cells....Beta Cells....

  • Introduction
  • An overview of the pathophysiology of T2DM - R DeFronzo
  • Addressing Beta Cells preservation - S Del Prato
  • Chairpersons : JJ Dalal, NV Deshpande, A Bhagwat
  • Debate - SPRINT to lower BP in day to day clinical practice
  • Proponent - T MacDonald
  • Opponent - N Poulter
  • Rebuttal I - T MacDonald
  • Rebuttal II - N Poulter
  • Q and A
  • Closing remarks

Day 2 : Saturday,1st Oct 2016

Hall B

11.00-12.30am



5min
10min
30min
5min
10min
10min
20min

USV
90mins with SGLT2 Inhibitors

  • Moderators - S Kale, S Sheikh
  • Experts : R DeFronzo, H Thacker, S Shaikh
  • Introduction - H Thacker
  • Clinical Insights- H Thacker
  • SGLT2i in diabetes-Status of Canagliflozin - R De Fronzo
  • Imp Points/ Issues S Shah
  • SGLT2i -Benefits beyond glycemic control-S Kale
  • Case Discussion Tips & Tricks- S Shaikh
  • Discussion - Moderators, Experts

12.30-2.00pm


5min
15min
18min
15min
30min
5min

Unisearch
90mins with Hypertension : Triple drug therapy

  • Chairpersons : N V Deshpande, K Venugopal
  • Introduction - NV Deshpande
  • Diuretic a main stay of therapy - T Nair
  • Concept of Combination therapy on HT - T MacDonald
  • Triple drug therapy : Single dose poly-pill - U Jadhav
  • Discussion
  • Closing remarks - K Venugopal

2.00-3.00pm

Lunch

3.00-4.30pm


5min
15min
20min
15min
30min
5min

Abbott
90mins with Vitamin K Antagonists

  • Chairpersons : A Banerjee , S Petkar
  • Introduction - A Banerjee
  • Vit K Antagonists in valvular AF - Soumitra Kumar
  • Vit K Antagonists for stroke prevention in era of NOAC's -J Camm
  • Vit K Antagonist : An Indian persepective - H M Mardikar
  • Discussion
  • Closing remarks - S Petkar

4.30-6.00pm


5min
15min

18min
20min
20min
5min

Emcure
90mins with AMI - Emergency care to secondary prevention

  • Chairpersons : S Bansal, A Jabir
  • Introduction - A Jabir
  • AMI in 3hrs : Pharmaco Invassive is the best strategy - MS Hiremath
  • Managing patient of AMI with cardiogenic shock - S Price
  • Emergency management to secondary prevention of AMI - C Granger
  • Discussion
  • Closing remarks - S Bansal

6.00-6.30pm

Break

6.30-8.00pm

22+8min
22+8min



16min
4min
16min
4min
10min

Beta Cells.....Beta Cells....Beta Cells....

  • Introduction
  • An overview of the pathophysiology of T2DM - R DeFronzo
  • Addressing Beta Cells preservation - S Del Prato
  • Chairpersons : JJ Dalal, NV Deshpande, A Bhagwat
  • Debate - SPRINT to lower BP in day to day clinical practice
  • Proponent - T MacDonald
  • Opponent - N Poulter
  • Rebuttal I - T MacDonald
  • Rebuttal II - N Poulter
  • Q and A
  • Closing remarks

Day 2 : Saturday,1st Oct 2016

Hall C

11.00-12.30 am


5min
22min
15min
18min
20min
5min

Pfizer
90mins with NOAC's

  • Chairpersons : A Naik, B Pinto
  • Introduction - A Naik
  • Navigating the evidence : Are all NOAC's the same? - C Granger
  • NOAC's in CKD - B Wrigley
  • AF and ACS-managing NOACS and antiplatelets - JJ Dalal
  • Discussion
  • Closing remarks - B Pinto

12.30-2.00pm


5min
15min
15min

20min
30min
5min

90mins with Heart failure with reduced ejection fraction

  • Chairpersons : MS Hiremath, JJ Dalal
  • Introduction - MS Hiremath
  • Optimizing treatment for any heart failure patient - JJ Dalal
  • Case based presentation : Treatment of patient who has recovered from ADHF - A Bhagwat
  • Is there a paradigm shift in management of HF? - L Ryden
  • Discussion
  • Closing remarks - JJ Dalal

3.00-4.30pm


5min
15min

15min
20min

30min
5min

Lupin
90mins with Hypercholesterolaemia

  • Chairpersons : N Desai, SS Iyengar
  • Introduction - N Desai
  • Familial Hyperclolesteremia clinical recognition and management - NV Deshpande
  • Statins plus ezetimibe : When to consider? - G Koshy
  • Hypercholesterolaemia - is there a place for PCSK9-inhibitor therapy? - F Raal
  • Discussion
  • Closing remarks - SS Iyengar

4.30-6.00pm




5min
15+5min
15+5min
15+5min
20min
5min

Sanofi
90 mins-New Insights with Basal Insulins & New GLP1 Analogue

  • Moderators - U Phadke, S Kale
  • Experts - Peter Gaede, Ambrish Mithal,Mathew John
  • Introduction - S Kale
  • Intensification of insulin treatment: New tools - M John
  • In-Hospital management of glycemia - A Mithal
  • Role of Basal Insulin and short acting GLP-1 - S Kale
  • Discussion
  • Closing remarks - S Kale

6.00-6.30pm

Break

6.30-8.00pm

22+8min
22+8min



16min
4min
16min
4min
10min

Beta Cells.....Beta Cells....Beta Cells....

  • Introduction
  • An overview of the pathophysiology of T2DM - R DeFronzo
  • Addressing Beta Cells preservation - S Del Prato
  • Chairpersons : JJ Dalal, NV Deshpande, A Bhagwat
  • Debate - SPRINT to lower BP in day to day clinical practice
  • Proponent - T MacDonald
  • Opponent - N Poulter
  • Rebuttal I - T MacDonald
  • Rebuttal II - N Poulter
  • Q and A
  • Closing remarks
Hall A Hall B

Day 3 : Sunday 2nd Oct 2016

Hall A :Hot topics in Cardio-Diabetes Therapeutics

9.00-10.30am


18+4min

18+4min
18+4min
18+4min

Hot topics in cardio-diabetes therapeutics

  • Chairpersons : U Jadhav , NV Deshpande, S Shah
  • Introduction
  • Treating hypertension in type 2 diabetes - A Solini
  • Hope III -Understanding and Misunderstanding
  • Lipid point of view - F Raal
  • HT point of view - N Poulter
  • Personalization of glucose-lowering therapy in Type 2 diabetes - S Del Prato
  • Q and A
  • Closing remarks

10.30-12.00noon



5min
20min


10min
15min

10min
15min
10min
5min

Novo Nordisk
90 Mins with GLP1 Analogue, Leader Experience

  • Moderators - A Bhoraskar, S Sheikh, S Kale
    Experts - Prof Lars Ryden, Prof Miles Fisher, Dr Uday Phadke, Dr.Mathew John
  • Introduction - A Bhoraskar
  • Getting to the heart of the matter: Implications from LEADER study - P Gaede
  • Q and A
  • Considering the Clinical Impact of Newer generation insulins for the Treatment of Type 2 Diabetes- M John
  • Q and A
  • GLP-1 analogues : Evolving landscape and clinical relevance - U Phadke
  • Q and A
  • Closing remarks - S Kale

12.00-1.30pm


22+8 mins
18+4mins
18+4mins

Obesity Symposium

  • Chairpersons : S Sheikh, U Phadke, L Ryden
  • Introduction
  • The Global Challenge of Obesity and Diabetes - L Ryden
  • Diabesity-What is New? - S Joshi
  • Bariatric surgery in diabetes-Endocrinologist's view - U Phadke
  • Q and A
  • Closing remarks

12.30pm

Lunch

Hall A Hall B

Day 3 : Sunday 2nd Oct 2016

Hall B

9.00-10.30am



16+12min
16+12min

16+12min

In conversation
With Dr Susanna Price and Dr Benjamin Wrigley

  • Conducted by - A Bhagwat and S Rao
  • Introduction
  • Non-cardiac surgery guidelines - what is relevant to intensivist - S Price
  • Oral anticoagulation for atrial fibrillation: interruption or bridging? - B Wrigley
  • How do we risk stratify and manage patients with syncope - S Petkar
  • Discussion
  • Closing remarks

10.30-12.00noon


5min
15min
15min
15min
30min
5min

Emcure
90mins with Management of Acute Ischemic Stroke

  • Chairpersons : R Mathew, PP Mohanan
  • Introduction : R Mathew
  • Thrombolysis in Acute Ischemic stroke : without stroke unit - U Jadhav
  • Thrombolysis in stroke unit - M Pradeep
  • Should cardiologists treat acute ischemic stroke? - HM Mardikar
  • Discussion
  • Closing Remarks : PP Mohanan

12.00-1.30pm


12+5min
12+5min
12+5min
12+5min
12+5min

CAD Update in short

  • Chairpersons : JJ Dalal, NV Deshpande, G Koshy
  • Introduction
  • BVS : Best vascular solution or a distant dream - S Rao
  • Cardiovascular safety of oral anti diabetic drugs - G Koshy
  • Peripartum cardiomyopathy - K Venugopal
  • Cardiac Biomarkers - the present & the future - B Pinto
  • The dilemma of dealing with intermediate ASCVD risk population - SS Iyengar
  • Discussion
  • Closing Remarks

12.30pm

Lunch

Hall A Hall B

Day 3 : Sunday 2nd Oct 2016

Hall III : Arrhythmia Update for daily practice

9.30-10.30am

ECG in day-to-day clinical Practice

  • Interactive case presentation I - ACS with LVF
  • Echocardiography in intensive care - pitfalls and potential use

11.00-12.30pm

Arrhythmia Update I- ECG in day-to-day Clinical practice

  • BroadQRS tachycardia
  • ECG in ACS
  • ECG in metabolic disorders

12.30-2.00pm

90mins with hyperlipidemia

  • Experts - Frederick Raal